| Literature DB >> 34536449 |
Anzhi Hu1, Huijuan Chen1, Jing Liang2, Cong Liu1, Fanzhu Li1, Chaofeng Mu3.
Abstract
Cell-based therapies could overcome the limitations of traditional drugs for the treatment of refractory diseases. Cell exchange between the bone marrow and blood is bidirectional. Several kinds of cells in the blood have the capability to enter the bone marrow by interacting with sinusoidal cells under specific physiological or pathological conditions. These cells are the potential living therapeutics or delivery vehicles to treat or prevent bone marrow-related hematologic diseases. In this review, we summarized the in vivo molecular mechanisms and kinetics of these cells in entering the bone marrow. The advances in the fabrication of living cell drugs and the strategies to design cell-based carriers into the bone marrow were discussed. The latest studies on how to use blood cells as living drugs or as drug carriers to improve therapeutic outcomes of hematologic diseases inside the bone marrow were highlighted.Entities:
Keywords: Bone marrow; Cell therapy; Cell-mediated drug delivery; In vivo kinetics; Leukemia
Mesh:
Substances:
Year: 2021 PMID: 34536449 DOI: 10.1016/j.jconrel.2021.09.018
Source DB: PubMed Journal: J Control Release ISSN: 0168-3659 Impact factor: 9.776